RU2077203C1 - Preparation for struggle against blood-sucking mosquito larvae - Google Patents

Abstract

FIELD: microbiology, insecticides. SUBSTANCE: invention proposes bactolarvicide-base preparation that has additionally spherolarvicide at ratio = 1:(1-10), by weight. Preparation shows efficacy against different species of blood-sucking mosquitos for the long time. EFFECT: enhanced effectiveness of preparation. 4 tbl

Description

 The invention relates to the microbiological industry, to the production of means of combating blood-sucking insects.

Domestic bacterial preparations for controlling larvae of blood-sucking mosquitoes are known, these are bactararvicide [1] bactoculicide [2] and spherolarvicide [3]
Commercial preparations known are Vectobac (firm Abot Labor-ftories) and Bactimos (firm Biochem Prod. SA Covargi et Solvio FR) and other rights to the production and distribution of which belong to manufacturing companies.

 Comparative studies of domestic and foreign drugs showed the high efficiency of domestic drugs, which allowed them to organize their own production in the form of powders and pastes. Bactolarvicide and Bactoculicide preparations are prepared on the basis of different strains of bacteria of the species Bacillus thuringiensis, therefore, many of their properties in combating mosquito larvae differ slightly and the choice of them for use in specific cases remains with the consumer.

 The preparation spherolarvicide is made on the basis of bacteria of the species Bacillus sphaericus and differs from bacterolarvicide and bactoculicide in spectrum and duration of action, therefore it is recommended for use in specific conditions with dirty water, the presence in biotopes, mainly mosquitoes of the genus Culex, etc.

 Bactolararicide at a dose of about 0.01 mg / l is effective against many species of larvae, it acts quite quickly (within 1–3 days), however, the drug is partially inactivated in the treated aquatic environment and its potential for action is significantly reduced by the end of the first week. Its longer action is associated with the effect of a preserved active principle.

 The preparation spherolarvicide is specific for mosquito larvae of the Culex genus, it acts more slowly, but longer, therefore it is recommended for the treatment of wastewater and other dirty waters, where bactarvaricide has no advantages.

 The main disadvantage of spherolarvicidal compared to bactararvicid is its low efficacy against larvae of malaria and other mosquito species, which very often breed in the same place as Culex larvae.

 Under natural conditions, as a rule, larvae of different mosquito species multiply simultaneously in one pond, other aquatic organisms interact with them, and the use of one of the preparations is often insufficient, especially at high temperatures, when the rate of development of new generation larvae increases significantly and at the time of their appearance, for example, after a week, the previously used preparation of bactararvicid is already removed from the medium, and the preparation of spherolarvicid is not very effective against malaria larvae mosquitoes.

 The objective of the present invention is to provide a drug that would preserve the spectrum of action of bactarvaricide, and would be able to exert an effect after use for a longer time.

 The solution to this problem is achieved by creating a drug based on bactarvaricide, to which the spherolarvicide drug is added in a ratio of 1: 1 10.0 by weight.

 Example 1

 The drug bactolarvicide is mixed in a ratio of 1: 1 by weight with the preparation of spherolarvicide. Dispersants and adhesives are added to the mixture, then the effectiveness of the starting preparations and the proposed preparation is determined on the larvae of different types of mosquitoes.

From the data of Table 1 it follows that the proposed apparatus exhibits a slightly greater effect compared to the initial preparations on larvae of different species, because LD _{50 of the} proposed drug below. The effectiveness of spherolarvicide against larvae of the species Anofeles and Aedes is manifested in a very large dose. For bactararvicide LD ₅₀ for Anofeles and Kuleks higher than for the proposed drug.

 Example 2

 Since the proposed preparation is intended for use in conditions where several species of mosquitoes breed simultaneously, the preparation was prepared as in Example 1, and then the duration of the proposed preparation was determined in comparison with the initial ones on the mixture of Culex + Anofeles larvae.

 In this case, the effectiveness was determined by replanting the larvae on the treated surface after 7 days after the use of the preparations (Table 2).

 The data table. 2 show that the proposed drug exhibits higher activity against a mixture of mosquito larvae, especially against Anofeles larvae.

 Example 3

 For a comparative check of the duration of action of the preparations, the proposed preparation was prepared as in example 1, while in one case the ratio of the initial preparations of bactarvaricide and spherolarvicide was 1: 1.5, in the second case 1:10. A mixture of Culex + Anofeles larvae was planted on the treated surface after 7, 13 and 15 days.

 As in example 2, it was shown that the liquid containing the monopreparation retains efficacy with respect to Culex larvae for more than 15 days, and with respect to Anofeles, its effectiveness decreases to the level of 18 34 within a week.

 Under these conditions, the proposed drug in tested ratios after 15 days retains a higher and more stable activity (Table 3).

 Example 4

 In order to verify the conclusions of Example 3, a field experiment was carried out by processing a plot of a rice check, where, along with others, mosquito larvae of the Kuleks and Anofeles species reproduced.

 The treatment of the plots was carried out with monopreparations and the proposed preparation prepared as in Example 1. The results were taken into account using more stable Anofeles larvae of the first age as an example.

 It was found that immediately after treatment, larvae of the 1st age die, however, after 7 days their number begins to increase (Table 4). Moreover, the increase in the number of larvae is more effectively inhibited by the proposed drug. The number of larvae in untreated areas is growing significantly.

 Thus, the proposed drug acts more efficiently for a longer time in a mixture of larvae of various species in laboratory and natural conditions.

Sources of information
1. Volzhinsky D.V. Sokolova E.I. Kulieva N.M. Experience in the development and use in the USSR of biological agents for combating blood-sucking mosquitoes using the example of bactarvaricide. thesis. doc. II Symposium of the CMEA member countries on microbial pesticides, May 15-19, 1990 Protvino), M. 1990, p.151.

 2. A.S. N1135024, USSR, MKIZ A 01 N 63/00. Strain Vas. thyringiensis (H) 171 Kandybin N.V. Barbashova N.M. (USSR), N 3575852-15; claimed 06.04.87, publ. 04/30/87, Bull. N 16. 270 c.

 3. Shevtsov VV Gaitan V.I. Kraynova O.A. et al. Study of the culture of Bacillus sphaericus as a promising biological agent for mosquito control. Thes. doc. and stand. message All conf. "Ways to improve microbiological control of harmful insects and plant diseases." Velegozh-Obolensk, 1986, p. 195-196.

 4. Van / Essen F.W. Simulated feieeld studies with pour Bacillus thuringiensis var. israelensis against mosguitoc: Recidnal activity and ffect on soid constitucuts.-Mosguito news, 1980, v. 42, N 1, p. 66-72.

 5. Fargnal A.J. Temerak S.A.-Zur Wirkung von Bacillus thuringiensis var. israelensis anf die larven der Stechmucke culex pipiens molestus.-Anz. Schadlingsk Pflaanzenschutz. Umweltschutz, 1982, 55, N 5, 89-93. me. Graw.Hills.

Claims (1)

 1 A preparation for combating larvae of blood-sucking mosquitoes containing bactararvicide, characterized in that it additionally contains spherolarvicide in a ratio of 1 1 10, respectively.

Images